Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunic "super excited" about latest PMS trial data By: News Direct October 11, 2023 at 05:15 AM EDT --News Direct--Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial assessing the potential of its treatment for progressive multiple sclerosis (PMS).Dr. Vitt expresses says he's "super excited" about the data, which he believes exceeded expectations. He adds that given the limited treatment options available for progressive MS, the company's findings are particularly significant.Immunic has observed a 22.4% reduction in the neurofilament light chain (NFL) biomarker, which correlates with better outcomes in preventing disability worsening in MS patients. This result was achieved with patients treated with 45 milligrams of their drug.The company has enrolled 467 patients in this 120-week phase two study, with final data expected around April 2025. Dr. Vitt also hints at upcoming updates from other programs as well as more news to come on a phase three clinical study.Contact DetailsProactive United States+1 347-449-0879action@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/immunic-super-excited-about-latest-pms-trial-data-876570218 Related Stocks: Immunic Inc Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Immunic "super excited" about latest PMS trial data By: News Direct October 11, 2023 at 05:15 AM EDT --News Direct--Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial assessing the potential of its treatment for progressive multiple sclerosis (PMS).Dr. Vitt expresses says he's "super excited" about the data, which he believes exceeded expectations. He adds that given the limited treatment options available for progressive MS, the company's findings are particularly significant.Immunic has observed a 22.4% reduction in the neurofilament light chain (NFL) biomarker, which correlates with better outcomes in preventing disability worsening in MS patients. This result was achieved with patients treated with 45 milligrams of their drug.The company has enrolled 467 patients in this 120-week phase two study, with final data expected around April 2025. Dr. Vitt also hints at upcoming updates from other programs as well as more news to come on a phase three clinical study.Contact DetailsProactive United States+1 347-449-0879action@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/immunic-super-excited-about-latest-pms-trial-data-876570218 Related Stocks: Immunic Inc